CAMBRIDGE, Mass. (May 9, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Kristin Neff, Vice President, Clinical Operations, will present at the Combined Canadian Spinal Cord and Ontario Spinal Cord Injury Research Network Meeting on Saturday, May 13, 2017 at 2:40 PM ET at the Marriott Eaton Center in Toronto, Ontario. Ms. Neff will present an abstract titled “Interim Clinical Results from the Ongoing INSPIRE Pivotal Study to Assess the Safety and Probable Benefit of the Investigational Neuro-Spinal Scaffold for Treatment of Acute Thoracic AIS A Spinal Cord Injury.”
Mark Perrin, Chairman and CEO, said, “The Canadian Spinal Cord and Ontario Spinal Cord Injury Research Network Meeting will be a great opportunity for us to continue to engage with the Canadian spinal cord injury research and care network, and we look forward to providing an update on the INSPIRE clinical results.”
For more information on the INSPIRE study, please visit the company’s ClinicalTrials.gov registration site: http://clinicaltrials.gov/ct2/show/study/NCT02138110.
About the Neuro-Spinal Scaffold™ Implant
Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in The INSPIRE Study for the treatment of patients with acute, complete (AIS A), thoracic traumatic spinal cord injury and a pilot study for acute, complete (AIS A), cervical (C5-T1) traumatic spinal cord injury. For more information on the cervical study, refer to https://clinicaltrials.gov/ct2/show/study/NCT03105882.